Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma

Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

ZUMA-12: Axicabtagene ciloleucel for high-risk large B cell lymphoma ( Prof Sattva Neelapu - MD Anderson Cancer Center, Houston, USA )

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma

Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA

Neurocognitive impairment in long-term survivors of childhood Hodgkin lymphoma ( Dr Annalynn M Williams - St. Jude Children's Research Hospital, Memphis, USA )

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in...

Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA

Venetoclax combined with AML induction/consolidation therapy with FLAG-IDA in newly diagnosed or R/R AML ( Dr Curtis Lachowiez - University of Texas MD Anderson Cancer Center, USA )

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-negative B-cell ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )

Ponatinib, venetoclax and dexamethasone for patients with relapsed or...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL...

Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )

Predictive factors for overall survival in chronic myeloid leukaemia patients:...

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )

Cranial radiation mostly eliminated in children with T-ALL and bortezomib...

Prof David Teachey - The University of Pennsylvania, Rutledge, USA

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic...

Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia ( Dr William Wierda - University of Texas MD Anderson Cancer Center, Houston, USA )

ecancer special issue on immunotherapy

Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy

ecancer special issue on immunotherapy ( Dr Nicola Fusco and Elham Sajjadi - European Institute of Oncology, Milan, Italy )

PARP inhibitors in prostate cancer: A promise delivered

Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA

PARP inhibitors in prostate cancer: A promise delivered ( Dr Abhishek Tripathi - Stephenson Cancer Center, Oklahoma City, USA )

More from ecancer